<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373568</url>
  </required_header>
  <id_info>
    <org_study_id>05--01</org_study_id>
    <nct_id>NCT00373568</nct_id>
  </id_info>
  <brief_title>Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis</brief_title>
  <official_title>Miltefosine (42 Days) for Mucosal Leishmaniasisi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Foundation</source>
  <brief_summary>
    <textblock>
      Miltefosine (longer course) will be used to try to improve the cure rate of mucosal
      leishmaniasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug
      for bolivian mucosal leishmaniasisi
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>December 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
  </secondary_outcome>
  <enrollment>25</enrollment>
  <condition>Leishmaniasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>miltefosine: 2.5 mg/kg/day for 42 days</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mucosal leishmaniasis

        Exclusion Criteria:

          -  No comcomitant disease as judged by laboratory and clinical parameters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Soto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIBIC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palos Blancos</name>
      <address>
        <city>Palos Blancos</city>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bolivia</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2006</study_first_submitted>
  <study_first_submitted_qc>September 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <last_update_submitted>May 29, 2010</last_update_submitted>
  <last_update_submitted_qc>May 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <keyword>mucosal</keyword>
  <keyword>miltefosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

